A computational model using the epigenome and trained on CRISPR drop-out screens can identify oncogenic dependencies in primary tumor samples

Chris Fiore, Matthew L Eaton, Brian Johnston, Matt Guenther, Cindy Collins, Mei Wei Chen, John Carulli, Eric Olson Syros Pharmaceuticals, 35 Cambridge Park Drive, Cambridge, MA

Abstract

The epigenome can reveal which resources a cancer cell has dedicated to maintaining the expression of key genes, which are often oncogenic dependencies. Previous efforts used super-enhancers (SEs), large regions of active chromatin, to identify these oncogenic dependencies. We previously used H3K27ac ChIP-seq to identify SEs in acute myeloid leukemia (AML) and identified a SE at the RARA gene locus in a subset of AML patients that represented a novel dependency. This led to a clinical trial for SY-1425, an agonist of RAR α (NCT02807558). Here we use H3K27ac ChIP-seq to expand on the concept of SEs and include other methods to quantify the effects of the epigenome on transcription, including MARGE and Activity by Contact, in order to identify oncogenic dependencies. Multiple variants and modifications of these scores are combined with additional properties of gene regulation, such as gene regulatory network (GRN) scores, into a machine learning model to predict the essentiality of genes from a genome-wide CRISPR screen in cancer cell lines. This new model, which we name PETCERF, outperforms previous individual epigenomic scores at identifying differential essential genes from H3K27ac ChIP-seq. The combination of many types of input variables was found to be important in the model predictions. Furthermore, after training the model on cell line data, we can then identify known and novel cancer dependencies as marked by the epigenome in primary tumor samples. This tool should be useful in identifying future candidate drug targets.

Super enhancers (SEs) can identify oncogenic dependencies

Some AML patients have a SE at the RARA locus



H3K27ac ChIP-seq tracks in AML patient samples, showing that an SE is present at the *RARA* locus in a subset of patients

RARA-high AML cell lines are sensitive to SY-1425



Proliferation assay of AML cell lines treated with SY-1425. RARA-high cell lines are sensitive to SY-1425, a RAR α agonist, and RARA-low are insensitive.





Many H3K27ac scores can quantify enhancers to identify oncogenic dependencies



• Based on DepMap CRISPR screen

Scores quantifying H3K27ac Scores using gene regulatory network (GRN) topology signal around genes to predict target (or TF) activity Super enhancers (SE) **Correlation networks DoRothEA** • Size of SE linked to nearby gene by Genes are linked to TFs with • From Garcia-Alonso *et al.* 2019 signal correlation or distance correlated expression • Curated set of gene to TF links • Published in Whyte et al. 2013 and from multiple other sources and McKeown et al. 2017 types of data **ARACNe** From Lachmann et al. 2016 VIPER Genes are linked to TFs with • All nearby H3K27ac signal weighted by high mutual information of • From Alvarez et al. 2016 distance to gene expression • Determines activity of TFs from • Based on Wang et al. 2016 expression of downstream targets Activity by contact (ABC) • H3K27ac weighted by strength of HiC References W. Whyte et al., Cell 153, 307-309 (2013). contacts to gene M.R. McKeown et al., Cancer Discov. 7, 1136–1153 (2017). • Based on Fulco et al. 2019 S. Wang et al., Genome Res. 26, 1417-1429 (2016). C.P. Fulco et al., Nat. Genet. 51, 1664-1669 (2019). .. Garcia-Alonso et al., Genome Res. 29, 1363-1375 (2019).

MARGE

Keystone Symposia







